that is ron square, ceo of array biopharma, just came out of presentation today.learn all about it. stay with cramer. >>> one man, one mission. >> i just want to make you money! >> eight years. tens of thousands of miles traveled. >> we're going to be -- >> hundreds of ceos. thousands of callers. millions of your e-mails and tweets. it all adds up to mm2k. this tuesday, 6:00 and 11:00 eastern on cnbc. clients are always learning more to make their money do more. (ann) to help me plan my next move, i take scottrade's free, in-branch seminars... plus, their live webinars. i use daily market commentary to improve my strategy. and my local scottrade office guides my learning every step of the way. because they know i don't trade like everybody. i trade like me. i'm with scottrade. (announcer) scottrade... ranked "highest in customer loyalty for brokerage and investment companies." >>> look, before we get to your tweets, we've got to do some housekeeping. back on september 17th, ken in my home state of new jersey, asked me about nektar therapeutics. it's nktr. this sto

that is ron squarer, the ceo of array biopharma. just giving a presentation today.ou can take a look and learn all about it. stay with cramer. >>> one man, one mission. >> i just want to make you money! >> eight years. tens of thousands of miles traveled. hundreds of ceos. thousands of callers. millions of your e-mails and tweets. it all adds up to mm2k. this tuesday, 6:00 and 11:00 eastern on cnbc. >>> look, before we get to your tweets, we've got to do some housekeeping. back on september 17th, ken in my home state of new jersey, asked me about nektar therapeutics. it's nktr. this stock just got crushed, fell 24% today. after nektar announced last night in an important clinical trial of their drug for chronic pain missed its primary end point. these are the kind of risks you run when you play with small-cap development stage biotechs. so what do you do with nektar now? i say wait for the dust to settle. this is a serious blow, but the company still has the rights to five drug candidates in phase three trials and having an r & d day october 8th. stay away for now a